- Yunnan Baiyao reported a net income of 1.70 billion yuan in the first quarter of 2024.
- The company made a total revenue of 10.77 billion yuan within the same period.
- The business is currently backed by twenty confirmed buys, a single hold, and zero sells.
A look at Yunnan Baiyao Group Co., Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Yunnan Baiyao Group Co., Ltd., a leading manufacturer of traditional Chinese medicines, is positioned for a positive long-term outlook. With a strong momentum score of 5, the company shows promising growth potential in the market. Its robust resilience score of 4 indicates a solid ability to weather uncertainties and challenges, further strengthening its standing in the industry. Additionally, a high dividend score of 4 suggests the company’s commitment to rewarding shareholders, adding to its appeal for investors.
Although the Value and Growth scores are moderate at 3, Yunnan Baiyao Group Co. remains well-rounded in its performance. As a diversified company with interests in pharmaceutical trading, capsules manufacturing, and hotel operations, it continues to show resilience and stability in its operations. Overall, with favorable scores across key metrics, Yunnan Baiyao Group Co. is positioned to maintain its strength and further drive value for its stakeholders in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
